[go: up one dir, main page]

AR087029A1 - Asociacion entre la n-hidroxi-4-{2-[3-(n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y el folfox - Google Patents

Asociacion entre la n-hidroxi-4-{2-[3-(n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y el folfox

Info

Publication number
AR087029A1
AR087029A1 ARP120102390A ARP120102390A AR087029A1 AR 087029 A1 AR087029 A1 AR 087029A1 AR P120102390 A ARP120102390 A AR P120102390A AR P120102390 A ARP120102390 A AR P120102390A AR 087029 A1 AR087029 A1 AR 087029A1
Authority
AR
Argentina
Prior art keywords
benzofuran
association
administered
folfox
dimethylaminomethyl
Prior art date
Application number
ARP120102390A
Other languages
English (en)
Inventor
Stephane Depil
Anne Jacquet-Bescond
Ioana Kloos
Anne Sarry
Sriram Laure-Balasubramanian
Joseph Buggy
Original Assignee
Servier Lab
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Pharmacyclics Inc filed Critical Servier Lab
Publication of AR087029A1 publication Critical patent/AR087029A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Asociación entra la N-hidroxi-4-{2-[3-(N,N-dimetilaminometil)benzofuran-2-ilcarbonil-amino]etoxi}benzamida de fórmula (1), o una de sus sales de adición a un ácido o a una base farmacéuticamente aceptable y el FOLFOX. Medicamentos.Reivindicación 2: Asociación según la reivindicación 1 caracterizada porque la N-hidroxi-4-{2-[3-(N,N-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida se utiliza en la forma de un hidrocloruro. Reivindicación 7: Asociación según una de las reivindicaciones 4 a 6 caracterizada porque los compuestos de la asociación se administran durante 5 días consecutivos, estando seguido este periodo de 9 días consecutivos sin ninguna administración. Reivindicación 8: Asociación según una de las reivindicaciones 4 a 6 caracterizada porque la N-hidroxi-4-{2-[3-(N,N-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida se administra durante 4 días consecutivos, mientras que el FOLFOX se administra del tercer al quinto día. Reivindicación 9: Asociación según una de las reivindicaciones 4 a 6 caracterizada porque la N-hidroxi-4-{2-[3-(N,N-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida se administra durante 4 días consecutivos, mientras que el oxaliplatino y el ácido folínico se administran simultáneamente el tercer día, infusión al cabo de la cual se administra el 5-fluorouracilo de manera continua hasta el quinto día.
ARP120102390A 2011-07-04 2012-07-02 Asociacion entre la n-hidroxi-4-{2-[3-(n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y el folfox AR087029A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1102087A FR2977492B1 (fr) 2011-07-04 2011-07-04 Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
US201161571789P 2011-07-05 2011-07-05

Publications (1)

Publication Number Publication Date
AR087029A1 true AR087029A1 (es) 2014-02-05

Family

ID=45063186

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102390A AR087029A1 (es) 2011-07-04 2012-07-02 Asociacion entre la n-hidroxi-4-{2-[3-(n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y el folfox

Country Status (6)

Country Link
US (1) US20150038513A1 (es)
EP (1) EP2785704A1 (es)
AR (1) AR087029A1 (es)
FR (1) FR2977492B1 (es)
HK (1) HK1203484A1 (es)
WO (1) WO2013004965A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017002858A (es) 2014-09-03 2017-10-24 Pharmacyclics Llc Sales novedosas de 3-[(dimetilamino)metil]-n-{2-[4-(hidroxicarbamo il)fenoxi]etil}-1-benzofuran-2-carboxamida, formas cristalinas relacionadas, metodo para preparar las mismas y las composiciones farmaceuticas que contiene las mismas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092115A2 (en) 2003-04-07 2004-10-28 Axys Pharmaceuticals Inc. Hydroxamates as therapeutic agents
WO2008141189A1 (en) * 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof
US20100292320A1 (en) * 2007-12-14 2010-11-18 Gilead Colorado, Inc. Benzofuran anilide histone deacetylase inhibitors
GB2462893B (en) * 2008-08-29 2010-10-13 Bayer Schering Pharma Ag N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
NZ591387A (en) * 2008-08-29 2012-03-30 Bayer Pharma AG N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b

Also Published As

Publication number Publication date
US20150038513A1 (en) 2015-02-05
EP2785704A1 (fr) 2014-10-08
FR2977492A1 (fr) 2013-01-11
FR2977492B1 (fr) 2013-07-05
WO2013004965A1 (fr) 2013-01-10
HK1203484A1 (en) 2015-10-30

Similar Documents

Publication Publication Date Title
CL2019001077A1 (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2019010736A (es) Inhibidor del antigeno de superficie del virus de la hepatitis b.
PE20210667A1 (es) Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
PA8791801A1 (es) Compuestos de pirazol
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
AR093659A1 (es) Derivados ciclicos de nucleosidos y usos de los mismos
AR067886A1 (es) Derivados de acido azabifenilaminobenzoico
AR073077A1 (es) Uso de dabigatran. compuesto. composicion farmaceutica-
MX2023000812A (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
AR058163A1 (es) Medicamentos exhaltadores del deseo sexual que comprenden derivados de benzimidazolona
UY30856A1 (es) Nuevos derivados de 2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y principalmente como inhibidores de ikk
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
AR087803A1 (es) N-hidroxi-4-{2-[3-n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y esquema para administrarla
AR079945A1 (es) Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3)
PH12015502429A1 (en) Dicarboxylic acid compound
MX2018013133A (es) Compuesto de pirazolo[1,5-a]pirimidina.
UY34050A (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol- 2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen
ES2478447T3 (es) Formulaciones del ácido desoxicólico y sus sales
AR077958A1 (es) Quinoxalinonas antagonistas de la hepcidina
MX391896B (es) Profármacos de fósforo de estimuladores de guanilato ciclasa soluble (sgc).
AR107937A1 (es) Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer

Legal Events

Date Code Title Description
FB Suspension of granting procedure